CD217 (IL-17Ra) Monoclonal Antibody (PAJ-17R), APC, eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody PAJ-17R recognizes mouse IL-17 receptor A (IL-17RA) also known as CD217
• This single transmembrane domain-containing receptor can homo- or heterodimerize with IL-17RC or IL-17RB
• IL-17RA binds to IL-17A, IL-17F(cytokines of the Th 17 lineage), or IL-17E (IL-25)
• Ligand binding to the single subunit of IL-17RA has been shown to induce homo- or heterodimerization of the receptor complex that in turn recruits Act-1 via the SEFIR domains leading to recruitment of TRAF6 and signaling through the NFkappaB and MAPK pathways
• Initial reports suggested ubiquitous expression of IL-17RA based on binding studies with IL-17-Fc and expression of mRNA
• Interestingly, despite this, not all cells expressing the receptor respond to IL-17A
• In particular, resting T cells do not respond
• It is not known if the expression level of IL-17RA protein varies or if some cells express the receptor but are not able to activate downstream signaling events
• Recent evidence suggests a more limited expression profile based on IL-17RA knock-out mice which display decreased numbers of neutrophils with impaired function in response to challenge with K
• pneumonia or Candida albicans
• This suggests IL-17RA plays a more domit and critical role in neutrophil development and function
• Our studies suggest that expression can be found on abundantly on Gr-1^dim population and many of the Gr-1^bright bone marrow cells, as well as some F4/80 positive cells
• Interleukin 17A (IL-17A) is a proinflammatory cytokine secreted by activated T-lymphocytes
• It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils
• IL-17RA is a ubiquitous type I membrane glycoprotein that binds with low affinity to IL-17A and IL-17F
• IL-17A and its receptor play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis
• Defects in IL-17RA are the cause of familial candidiasis type 5 (CANDF5) which is a rare disorder with altered immune responses and impaired clearance of fungal infections.